At the time of writing, Lexicon Pharmaceuticals Inc [LXRX] stock is trading at $0.61, up 7.65%. An important factor to consider is whether the stock is rising or falling in short-term value. The LXRX shares have gain 15.36% over the last week, with a monthly amount drifted -3.75%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Lexicon Pharmaceuticals Inc [NASDAQ: LXRX] stock has seen the most recent analyst activity on March 05, 2025, when Leerink Partners downgraded its rating to a Market Perform and also revised its price target to $1 from $2. Previously, H.C. Wainwright started tracking the stock with Buy rating on June 17, 2024, and set its price target to $10. On April 30, 2024, Leerink Partners initiated with a Outperform rating and assigned a price target of $5 on the stock. Jefferies started tracking the stock assigning a Hold rating and suggested a price target of $3 on March 07, 2023. Piper Sandler initiated its recommendation with a Overweight and recommended $10 as its price target on August 12, 2022. JP Morgan upgraded its rating to Neutral for this stock on January 29, 2021, but kept the price target unchanged to $7. In a note dated January 29, 2021, Wedbush downgraded an Neutral rating on this stock and boosted its target price from $2 to $8.
For the past year, the stock price of Lexicon Pharmaceuticals Inc fluctuated between $0.28 and $2.45. Currently, Wall Street analysts expect the stock to reach $6 within the next 12 months. Lexicon Pharmaceuticals Inc [NASDAQ: LXRX] shares were valued at $0.61 at the most recent close of the market. An investor can expect a potential return of 883.61% based on the average LXRX price forecast.
Analyzing the LXRX fundamentals
According to Lexicon Pharmaceuticals Inc [NASDAQ:LXRX], the company’s sales were 31.21M for trailing twelve months, which represents an 11.68% jump. Gross Profit Margin for this corporation currently stands at 0.98% with Operating Profit Margin at -5.69%, Pretax Profit Margin comes in at -5.68%, and Net Profit Margin reading is -5.68%. To continue investigating profitability, this company’s Return on Assets is posted at -0.6, Equity is -1.03 and Total Capital is -0.95. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.34.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
It is important to note that Lexicon Pharmaceuticals Inc [NASDAQ:LXRX] has a current ratio of 2.22. On the other hand, the Quick Ratio is 2.22, and the Cash Ratio is 0.57. Considering the valuation of this stock, the price to sales ratio is 7.14, the price to book ratio is 1.81.
Transactions by insiders
Recent insider trading involved COATS LONNEL, Former Affiliate, that happened on Aug 15 ’24 when 0.3 million shares were purchased.
